EPI-005 is under clinical development by Ethicann Pharmaceuticals USA and currently in Phase III for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase III drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EPI-005 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EPI-005 overview

EPI-005 is under development for the treatment of post-traumatic stress disorder (PTSD). It is administered as an oral disintegrating tablet. The drug candidate is a fixed dose combination of cannabidiol (CBD) and tetrahydrocannabinol (THC).

Ethicann Pharmaceuticals USA overview

Ethicann Pharmaceuticals is a pharma company that uses botanically sourced cannabinoid oils to formulate ethical drugs. It is headquartered in Toronto, Ontario, Canada.

For a complete picture of EPI-005’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.